Access Biotechnology led a $135m Series B round in Hemab, a clinical-stage biotechnology company, with participation from Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, Maj Invest Equity, Novo Holdings, RA Capital Management, and HealthCap. "Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need," Benny Sorensen, Hemab CEO and President.